Inderjit Mehmi, MD

Inderjit Mehmi, MD, medical oncologist, discusses the rationale for investigating the combination of fianlimab and cemiplimab in patients who have advanced melanoma with poor-risk features

Inderjit Mehmi, MD, discusses results from a subgroup analysis of patients with advanced melanoma and poor-risk features given fianlimab and cemiplimab in a phase 1 trial.